Literature DB >> 6985247

Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.

E F Wheelock, M K Robinson, G A Truitt.   

Abstract

The L5178Y-cell tumor dormant state in DBA/2 mice is an excellent model for assessing immunologically mediated tumor-growth restraint mechanisms associated with establishment and control of a tumor dormant state. It has enabled us to relate components of the host's tumor suppressive immune system to the stage of tumor dormancy and the magnitude of the tumor burden. A strong CTL response has been associated with establishment of the tumor dormant state and can be reelicited in vivo or in vitro, after its initial decline, by reexposure to tumor antigen. This reelicitation is mediated via immunologic stimulation of memory CTL. Combined cultures of NAD T-lineage lymphocytes and macrophages from tumor dormant mice produce considerable cytolytic activity where little or no activity can be detected in the individual populations. Based on the similar pattern of tumor target cell specificity of the two responses, it is likely that memory CTL contribute to this synergistic cytolytic activity. The synergistic cytolytic response persists after CTL activity has waned to undetectable levels and is probably the predominant cytolytic activity associated with maintenance of the tumor dormant state. However, this activity may be obscured by proliferation of endogenous tumor cells, which in turn triggers direct macrophage-mediated cytolytic activity. The target cell specificity of this direct macrophage-mediated cytolytic response is also similar to the CTL response suggesting T cell (or memory CTL) involvement in its generation. The L5178Y-cell tumor dormant model is well suited for attempts at cure with immunotherapy. Active specific and nonspecific immunotherapy are each capable of eliminating all tumor cells from approximately 50% of tumor dormant mice. The L5178Y-cell tumor dormant state is one of several animal models of tumor dormancy. The great variety of growth restraint mechanisms that control tumor dormant states in animal systems is strong evidence that tumor dormant states exist in cancer in human beings.

Entities:  

Mesh:

Year:  1982        PMID: 6985247     DOI: 10.1007/BF00049479

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  48 in total

1.  Partial characterization of anti-tumor effector macrophages in the peritoneal cavities of concomitantly immune mice and mice injected with macrophage-stimulating agents.

Authors:  K E Hopper; J Harrison; D S Nelson
Journal:  J Reticuloendothel Soc       Date:  1979-09

2.  Induction of cytocidal macrophages after in vitro interactions between Listeria-immune T cells and macrophages--role of H-2.

Authors:  A G Farr; W J Wechter; J M Kiely; E R Unanue
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

3.  Development of cell-mediated antiviral immunity and macrophage activation in C3H/HeN mice infected with mouse mammary tumor virus.

Authors:  A Tagliabue; D Boraschi; J L McCoy
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

4.  Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor.

Authors:  I F Tannock
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

Review 5.  The role of macrophages in defense against neoplastic disease.

Authors:  M H Levy; E F Wheelock
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

6.  Identification of macrophage-mediated cytolytic activity as a tumor suppressive mechanism during maintenance of the L5178Y-tumor dormant state in DBA/2 mice.

Authors:  M K Robinson; E F Wheelock
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

7.  Susceptibility of Friend virus antigen-modulated erythroleukemic cells to lysis by T lymphocytes from mice with dormant Friend virus infections.

Authors:  E V Genovesi; P A Marx; E F Wheelock
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

8.  Non-T-cell-mediated cytotoxicity in MSV tumor-bearing mice. III. Macrophage-mediated cytotoxicity against autochthonous MSV tumor-isolated target cells.

Authors:  S Becker; S Haskill
Journal:  Int J Cancer       Date:  1980-04-15       Impact factor: 7.396

9.  Active specific immunotherapy of murine leukemia. I. Irradiated tumor cell vaccine.

Authors:  G L Bartlett; J W Kreider; D M Purnell
Journal:  Int J Cancer       Date:  1979-11-15       Impact factor: 7.396

10.  Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice.

Authors:  N Minato; B R Bloom; C Jones; J Holland; L M Reid
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

View more
  1 in total

1.  Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.

Authors:  Ilia N Buhtoiarov; Alexander L Rakhmilevich; Lewis L Lanier; Erik A Ranheim; Paul M Sondel
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.